Author Claim Review

 Quick Explanation Copied

 Long Explanation

Flagship Contribution: FUNDC1 Mitophagy and Muscle-Adipose Crosstalk

The strongest signal in this author portfolio is the 2018 Cell Reports study, which demonstrates that skeletal-muscle-specific FUNDC1 deficiency paradoxically protects against high-fat-diet obesity via a ROS→ATF4→FGF21 endocrine axis driving adipose beiging Cell Reports FUNDC1 mitophagy-obesity paper. Methodological rigor is high: two independent Cre lines address off-target recombination, FGF21-DKO and antibody-blocking experiments establish necessity (not just correlation), and n≈6–14 per group with GEO data deposition support reproducibility. Reported effect sizes are large and internally consistent:

The accompanying 2020 review (235 references, corresponding author) synthesizes PINK1/Parkin, FUNDC1, BNIP3/NIX, and PHB2 pathways with AMPK/mTOR and NAD+/SIRT1 regulation, confirming sustained field leadership ARS mitophagy-metabolism review.

Adjacent and Peripheral Work

Directly connected to the mitophagy theme is a 2025 lncRNA/autophagy atherosclerosis study (CARMN–CSNK1A1–AKT/ATG7 axis) with in vivo ApoE-/- validation (n=6/group) and mechanistic rescue experiments CARMN autophagy atherosclerosis paper. A high-quality 2026 computational paper (MAP framework, 694,246-edge knowledge graph) and 2026 SCALE virtual-cell model both score 9/9 on extracted quality and novelty, though they may reflect a different Quan Chen MAP single-cell drug-response framework SCALE virtual-cell perturbation model.

Critical Blindspots and Name Ambiguity

Several papers (triazole-benzisoselenazolone chemistry, titanium implants, Tm:Ho:GdVO4 lasers, arylsulfonyl carbanion kinetics) almost certainly belong to different Quan Chens — a serious homonym confound given the common Chinese name Triazole-benzisoselenazolone antiproliferative study Arylsulfonyl halomethyl carbanion kinetics study. The OpenAlex author query returned a 429 rate-limit error, so h-index/citation counts could not be independently verified — a material gap for quantitative bibliometric assessment. Known limitations in the flagship work include female-biased cohorts, mouse-to-human translation gaps, incomplete exploration of alternative myokines, and partial heart FUNDC1 reduction in the MCK-Cre line Cell Reports FUNDC1 limitations. Confidence in the mitophagy-author assessment: high (strong mechanistic chain, data deposition); confidence in attributing peripheral papers: low.

 BGPT Author Review

Scientific Quality

The mitophagy Quan Chen demonstrates world-class mechanistic biology: dual Cre-driver conditional knockouts, necessity experiments (FGF21 DKO, antibody blocking), multi-omics with GEO deposition, and a highly cited 235-reference review anchoring the field. The Cell Reports paper's paradoxical finding (mitophagy deficiency protecting against obesity) required unusually careful causal chain-building. However, the portfolio mixes in weaker clinical work (score 5) and many likely-homonym papers, diluting attributable strength; citation metrics could not be verified due to OpenAlex rate-limiting. Deducting for inability to confirm track record breadth and some mid-tier outputs.

Communication Quality

The flagship paper communicates a complex muscle-adipose endocrine axis with clear mechanistic figures and transparent limitation acknowledgment; the review is well-organized across pathways and tissues. Weaknesses: dense multi-panel figures typical of Cell Reports style, and the 2020 review lists an author set that includes an apparently erroneous 'Mary Liebert' (the journal publisher) — a metadata sloppiness red flag. Peripheral papers show variable clarity.

Author Novelty

The 2018 finding that impairing mitophagy protects against dietary obesity via FGF21-mediated inter-organ signaling was genuinely counterintuitive and opened a mitohormesis subfield; the FUNDC1 receptor pathway itself was co-pioneered by this group. The 2026 computational work (MAP/SCALE) is cutting-edge but attribution is uncertain. The 2025 CARMN lncRNA study is solid but incremental within lncRNA-autophagy literature.

Scientific Rigor

Strong rigor signals: two independent Cre lines to control for off-target recombination, FGF21 double-knockout and neutralizing-antibody necessity tests, autophagy flux assays with colchicine, raw data deposited in GEO (GSE99803), blinded histology in the HBV clinical study, and declared non-competing interests with funding transparency. Weaknesses: sex bias in mouse cohorts, retrospective single-center clinical design, and no direct structural confirmation in the scFv disulfide study (modeling-only). The erroneous author name in the 2020 review metadata suggests some citation hygiene lapses.